

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

... of the ... to indicated in the ...

Figure 1 shows the results of the regression analysis. The dependent variable is the number of days of absence from work due to illness. The independent variables are the age, sex, and education of the respondent, the number of children in the household, the number of hours worked per week, and the number of days of absence from work due to illness in the previous year. The results show that the number of days of absence from work due to illness is positively related to the age of the respondent, the number of children in the household, and the number of days of absence from work due to illness in the previous year. The number of days of absence from work due to illness is negatively related to the sex of the respondent (female) and the number of hours worked per week. The results also show that the number of days of absence from work due to illness is positively related to the education of the respondent, but this relationship is not statistically significant.

6798	6799	6800	6801	6802
6803	6804	6805	6806	6807
6808	6809	6810	6811	6812
6813	6814	6815	6816	6817
6818	6819	6820	6821	6822
6823	6824	6825	6826	6827
6828	6829	6830	6831	6832
6833	6834	6835	6836	6837
6838	6839	6840	6841	6842
6843	6844	6845	6846	6847
6848	6849	6850	6851	6852
6853	6854	6855	6856	6857
6858	6859	6860	6861	6862
6863	6864	6865	6866	6867
6868	6869	6870	6871	6872
6873	6874	6875	6876	6877
6878	6879	6880	6881	6882
6883	6884	6885	6886	6887
6888	6889	6890	6891	6892
6893	6894	6895	6896	6897
6898	6899	6900	6901	6902
6903	6904	6905	6906	6907
6908	6909	6910	6911	6912
6913	6914	6915	6916	6917
6918	6919	6920	6921	6922
6923	6924	6925	6926	6927
6928	6929	6930	6931	6932
6933	6934	6935	6936	6937
6938	6939	6940	6941	6942
6943	6944	6945	6946	6947
6948	6949	6950	6951	6952
6953	6954	6955	6956	6957
6958	6959	6960	6961	6962
6963	6964	6965	6966	6967
6968	6969	6970	6971	6972
6973	6974	6975	6976	6977
6978	6979	6980	6981	6982
6983	6984	6985	6986	6987
6988	6989	6990	6991	6992
6993	6994	6995	6996	6997
6998	6999	7000	7001	7002

$$\sum_{j=0}^{\infty} \frac{1}{(n+j)^2} = \frac{1}{n(n-1)} + \sum_{j=1}^{\infty} \frac{1}{(n+j)^2}$$
[illegible]

DEFIN

Query Match: 92.44% Score 19.41 DB 29 Length 54245
 Best Local Similarity: 95.20% Prod. No. 3100021
 Matches: 297 Conserved: 6 Mismatches: 1 Pct Id: 94.3%

ID

1 AC006046:AAAAATAAAAAT 21
 1 TTTTCTTTTTTTTT

10 42590 AC006046:AAAAATAAAAAT 42570

RESULT

AC006046
 LOCUS Homo sapiens BAC clone RP11 458K11 from 2, complete sequence.
 DEFINITION AC006046 AC0060417
 VERSION AC006046.1 GI:119837915
 KEYWORDS BAC

SOURCE

ORGANISM Homo sapiens.
 Bacteria; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 (bases 1 to 199721)
 Gattalon, J.B., and Waterston, R.

Toward a complete human genome sequence.
 Science 265: 3 (11), 1997 1168 (1998)

MEDLINE

99064792
 0947074

REFERENCE

2 (bases 1 to 199721)
 Alt, F., Gattalon, M., and Spalding, L.

The sequence of Homo sapiens BAC clone RP11 458K11
 Unpublished (2001)

REFERENCE

3 (bases 1 to 199721)
 Waterston, R.H.

Direct Submission
 Submitted (10 SEP 2001) Genome Sequencing Center, Washington
 University School of Medicine, 4444 Forest Park Parkway, St. Louis,

REFERENCE

4 (bases 1 to 199721)
 Mo, G.108, USA

REFERENCE

5 (bases 1 to 199721)
 Waterston, R.H.

Direct Submission
 Submitted (29 MAR 2002) Genome Sequencing Center, Washington
 University School of Medicine, 4444 Forest Park Parkway, St. Louis,

REFERENCE

6 (bases 1 to 199721)
 Waterston, R.H.

Direct Submission
 Submitted (16 APR 2002) Department of Genetics, Washington
 University, 4444 Forest Park Avenue, St. Louis, Missouri 63110, USA

COMMENT

on Mar 29, 2002 this sequence version replaced at:15624963.
 Genome Center
 Contact: Washington University Genome Sequencing Center
 Center code: WHSG
 Web site: <http://www.genome.wustl.edu/>
 Contact: sapions@genome.wustl.edu
 Summary Statistics
 Contact: Project Name: HNR0458K11
 Drafting Center: WUGR

NOTE: This sequence may not represent the entire insert of this
 clone. It may be shorter because we only sequence overlapping
 clone sections once, or longer because we provide a small overlap
 between neighboring data submissions.

This sequence was finished as follows unless otherwise noted:
 all regions were double stranded, sequenced with an alternate
 chemistry, or covered by high quality data (i.e., paired quality
 40); an attempt was made to resolve all sequencing problems, such
 as compressions and repeats; all regions were covered by sequence
 from more than one subclone; and the assembly was validated by
 restriction digest.

MAPPING INFORMATION

Mapping information for this clone was provided by the following:
 McPherson, Department of Genetics, Washington University, St. Louis,
 MO. For additional information about the map, please visit the
 sequence page <http://genome.wustl.edu/458k11>

SOURCE INFORMATION

The RP11 Human BAC Library was made from the blood of one male
 donor, as described by (Sawada, K., Watanabe, T., Hayashi, T.,
 Latone, M., Furumasa, S., and the International Human Genome
 Mapping Consortium, 1996). The clone may be obtained either from
 the source or from the <http://www.genome.com> or from the Gene
 Bank. <http://www.ncbi.nlm.nih.gov/Genbank/Genbank.html>
 VECTOR: pBR322

RESEARCH PROJECT INFORMATION

The clone sequenced to the left is RP11 458K11. The clone sequenced
 to the right is RP11 219H24. Actual start of this clone is at base
 position 1 of RP11 458K11; actual end is at base position 1 of
 RP11 458K11.

The region from 147669 to 147702 (4 bases) of this clone may be covered
 by PCR products from clone DNA. Single-strand extension exist
 between 147661 and 147669. Polymorphisms exist between A562636 and
 A562636, data from A562635 and A562636 was used to finish
 A562636.

The sequence of AC0060417 has been incorporated into A562636.

FEATURES

Location/Qualifiers
 1..199721
 Zonedism: "Homo sapiens"
 ZBR: "311" "311" "0.06"
 Zchromosome: "2"
 Zmap: "2"
 Zclone: "RP11 458K11"
 Zclone: "116" "RP11 11"
 repeat region 1..287
 Zpt_family: "Alu"
 repeat region 1066..1248
 Zpt_family: "RFB"
 repeat region 1256..1558
 Zpt_family: "Alu"
 repeat region 1559..1829
 Zpt_family: "L2"
 repeat region 1830..2142
 Zpt_family: "Alu"
 repeat region 2143..2427
 Zpt_family: "L2"
 repeat region 2474..2757
 Zpt_family: "Alu"
 repeat region 2761..3076
 Zpt_family: "Alu"
 repeat region 3145..3649
 Zpt_family: "MafB"
 repeat region 3653..3954
 Zpt_family: "Alu"
 repeat region 4149..4314
 Zpt_family: "Alu"
 repeat region 4832..4858
 Zpt_family: "(TTT)u"
 repeat region 4867..5177
 Zpt_family: "Alu"
 repeat region 5178..5212
 Zpt_family: "(TTT)u"
 repeat region 5213..5469
 Zpt_family: "Alu"
 repeat region 5650..5818
 Zpt_family: "Alu"
 misc_feature 5853..5968
 Znote: "match to HNR0458K11 (5853-5968) (15624963)"
 misc_feature 5969..5969
 Znote: "match to HNR0458K11 (5969-5969) (15624963)"

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

1. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

2. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

3. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

4. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

5. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

6. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

7. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

8. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

9. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

10. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

11. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

12. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

13. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

14. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

15. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

16. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

17. The following information was obtained from the file of the FBI, New York City, dated 11/18/88, and is being furnished to you for your information.

disorders (such as hypertriglyceridemia, dyslipidemia, atherosclerosis, coronary artery disease, cerebrovascular disease or peripheral vascular disease), inflammation (such as sinusitis, asthma, pancreatitis, osteoarthritis, rheumatoid arthritis or arago), body weight disorders (such as obesity, cachexia or anorexia), psychiatric disorders, cancer, cystic fibrosis, premenstrual syndrome, diabetes, and diabetic complications. (1) or (11) is useful as research agent and materials for discovery of treatments and diagnostics for a disease, particularly human disease. (11) is useful for constructing nucleotide probes and primers, for detecting genetic polymorphism, for detecting changes in the level of expression of (11), and as a diagnostic tool. This sequence encodes a protein regulated by fatty acids.

Sequence: 2187 bp; 706 A; 548 G; 576 C; 664 T; 0 Other;

Query Match 82.9%; Score 17.4; DB 24; Length 2187;

Best Local Similarity 94.7%; Prod. No. 4,860,02;

Matches 10; Conservation 0; Mismatches 1; Indels 0; Gaps 0;

2 1-AAAAAGAAAAGTAAAAA 20

11111111111111111111

3 1-AAAAAGAAAAGTAAAAA 55

PESTILL 14

AKK1094

AKK1094 standard; cDNA; 4003 bp.

AC AKK1094;

1 24 JUN 2002 (first entry)

cDNA encoding human acyltransferase, AC1P 1.

human; acyltransferase; AC1P 1; antidiabetic; antilipemic; anorectic; antitumor; anorectic; cardioprotective; anorectic; ophthalmologic; cardiac; metabolic disorder; energy homeostasis disorder; diabetes; hyperlipemia; hypercholesterolemia; hyperlipoproteinemia; stroke; hypertriglyceridemia; hyperlipidemia; atherosclerosis; obesity; retinopathy; nephropathy; peripheral neuropathy; weight disorder; appetite regulation disorder; cachexia; anorexia; bulimia; cardiovascular disorder; gene; SS.

Homologous.

Key Location/Qualifiers

676 511..2627

/*trn4 4

/product "Human acyltransferase AC1P 1"

/note "the coding region is specifically claimed

in claim 1"

W200206950 A2.

26 FEB 2002.

21 AUG 2001 2001W 3526-259.

21 AUG 2000 2000US 2245009.

(PCT) 3 MILLERIN 2000000 107.

Kaplan; Liberman; K; Logan 11;

W11 2002 267664/2.

PE3346; AA079 03.

New acyltransferase 1, specifically glycerol 3-phosphate

acyltransferase, metabolic acids and proteins, useful for treating or

diagnosing e.g. metabolic disorders, weight disorders and appetite

regulation disorders

claim 1; Fig 1; 124pp; English.

XX the invention relates to acyltransferase (AC1P 1) nucleotide acids and proteins. These are useful as modulating agents in treating a variety of cellular processes (e.g., cellular metabolism, energy homeostasis, and/or cellular proliferation, growth, differentiation, and/or maturation), the amino acids, proteins, protein homeostasis, treatments, and therapies, peptides, peptidomimetics and small molecules can be used in screening assays, predictive medicine (e.g., diagnostics or prognostic assays), monitoring clinical trials, and pharmacogenetics; and in methods of treatment (e.g., therapeutic or prophylactic). The AC1P 1 polypeptide and its fragments are useful as reagents or targets in assays for the treatment and/or diagnosis of AC1P 1 mediated or related disorders, which include metabolic disorders such as disorders of energy homeostasis, e.g., diabetes, impaired glucose tolerance, insulin resistance, type 2 diabetes, hypercholesterolemia, hypertriglyceridemia, hyperlipoproteinemia, and/or hyperlipidemia; diabetic complications including atherosclerosis, stroke, retinopathy, nephropathy, and peripheral neuropathy; weight disorders and appetite regulation disorders, e.g., obesity, cachexia, anorexia and bulimia. Proteins may also be used to screen for compounds that occur in AC1P 1 substrates, to screen for drugs or compounds which modulate AC1P 1 expression and/or their disorders and/or related by insufficient or excessive production of AC1P 1 protein, the nucleotide acids may be used as hybridisation probes or primers, to express AC1P 1 protein, to detect AC1P 1 mRNA or a nucleotide sequence in an AC1P 1 gene, to modulate AC1P 1 activity, in chromosome mapping, tissue typing and forensic biology, and as surrogate markers (e.g., markers for prognosis or disease states, for predisposition or disease states, or their activity or of the pharmacodynamic profile of a drug). Modulators of AC1P 1 protein activity or nucleotide acids may be used as reagents or substrates having a cardiovascular disorder or a metabolic and/or energy disorder characterised by aberrant AC1P 1 protein activity, e.g., obesity, acid expression, and/or AC1P 1 antibodies can be used to detect and/or isolate AC1P 1 proteins, regulate the bioavailability of AC1P 1 proteins, and modulate AC1P 1 activity. The present sequence represents the coding sequence of human AC1P 1.

Sequence: 4003 bp; 826 A; 638 G; 698 C; 794 T; 2 Other;

Query Match 82.9%; Score 17.4; DB 24;

Best Local Similarity 94.7%; Prod. No. 4,860,02;

Matches 10; Conservation 0; Mismatches 1; Indels 0; Gaps 0;

2 1-AAAAAGAAAAGTAAAAA 20

11111111111111111111

3 1-AAAAAGAAAAGTAAAAA 55

PESTILL 14

AA05221

AA05221 standard; cDNA; 4211 bp.

AC AA05221;

25 JUN 2002 (first entry)

Human; RNP 4 cDNA.

Human; transferase; developmental disorder; obesity; retinopathy; nephropathy; inflammatory disorder; autoimmune disorder; parasitic infection;

inflammatory disorder; endocrine; antiparasitic; immunosuppressive;

cytostatic; neurotoxic; gene; SS.

Homologous.

Key Location/Qualifiers

676 511..2627

/*trn4 4

/product "Human; RNP 4 protein"

W200206950 A2.

26 FEB 2002.

21 AUG 2001 2001W 3526-259.

21 AUG 2000 2000US 2245009.

(PCT) 3 MILLERIN 2000000 107.

Kaplan; Liberman; K; Logan 11;

W11 2002 267664/2.

PE3346; AA079 03.

New acyltransferase 1, specifically glycerol 3-phosphate

acyltransferase, metabolic acids and proteins, useful for treating or

diagnosing e.g. metabolic disorders, weight disorders and appetite

regulation disorders

claim 1; Fig 1; 124pp; English.

US 09 004 395 395
 Patent No. 6121419
 GENERAL INFORMATION

APPLICANT: Bowyer, Daniel D.
 ADDRESS: Dallas, Mar 1, 1996
 TITLE OF INVENTION: COMBINING AND METHOD FOR
 TITLE OF INVENTION: COMBINING AND METHOD FOR
 NUMBER OF INVENTION: 8
 NUMBER OF INVENTION: 8
 CORRESPONDENCE ADDRESS:
 ADDRESS: Arnold, White & Burke
 STREET: P. O. Box 4433
 CITY: Houston
 STATE: Texas
 COUNTRY: USA
 ZIP: 77210
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: 395-395-395
 FILING DATE: 1996-06-17
 CLASSIFICATION: 4.45
 NAME: Parker, David L.
 REGISTRATION NUMBER: 42,165
 TELEPHONE: (512) 474-7577
 TELEFAX: (512) 474-7577
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 1420 base pairs
 TYPE: nucleic acid
 ORGANISM: Human
 MOLBULE TYPE: DNA (genomic)
 US 09 004 395 395

Query Match: 77.1% Score 16.21 Id 1 Length 1420
 Best Local Similarity: 85.7% Prod. No. 395
 Matches: 18, Conservation: 3, Mismatches: 3, Gaps: 0

US 09 004 395 395
 Patent No. 6121419
 GENERAL INFORMATION

APPLICANT: Bowyer, Daniel D.
 ADDRESS: Dallas, Mar 1, 1996
 TITLE OF INVENTION: COMBINING AND METHOD FOR
 TITLE OF INVENTION: COMBINING AND METHOD FOR
 NUMBER OF INVENTION: 8
 NUMBER OF INVENTION: 8
 CORRESPONDENCE ADDRESS:
 ADDRESS: Arnold, White & Burke
 STREET: P. O. Box 4433
 CITY: Houston
 STATE: Texas
 COUNTRY: USA
 ZIP: 77210
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: 395-395-395
 FILING DATE: 1996-06-17
 CLASSIFICATION: 4.45
 NAME: Parker, David L.
 REGISTRATION NUMBER: 42,165
 TELEPHONE: (512) 474-7577
 TELEFAX: (512) 474-7577
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 1420 base pairs
 TYPE: nucleic acid
 ORGANISM: Human
 MOLBULE TYPE: DNA (genomic)
 US 09 004 395 395

CITY: Houston
 STATE: Texas
 COUNTRY: USA
 ZIP: 77210
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: 395-395-395
 FILING DATE: 1996-06-17
 CLASSIFICATION: 4.45
 NAME: Parker, David L.
 REGISTRATION NUMBER: 42,165
 TELEPHONE: (512) 474-7577
 TELEFAX: (512) 474-7577
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 1420 base pairs
 TYPE: nucleic acid
 ORGANISM: Human
 MOLBULE TYPE: DNA (genomic)
 US 09 004 395 395

Query Match: 77.1% Score 16.21 Id 1 Length 1420
 Best Local Similarity: 85.7% Prod. No. 395
 Matches: 18, Conservation: 3, Mismatches: 3, Gaps: 0

US 09 004 395 395
 Patent No. 6121419
 GENERAL INFORMATION

APPLICANT: Board of Regents
 ADDRESS: The University of Texas System
 TITLE OF INVENTION: COMBINING AND METHOD FOR
 TITLE OF INVENTION: COMBINING AND METHOD FOR
 NUMBER OF INVENTION: 8
 NUMBER OF INVENTION: 8
 CORRESPONDENCE ADDRESS:
 ADDRESS: Arnold, White & Burke
 STREET: P. O. Box 4433
 CITY: Houston
 STATE: Texas
 COUNTRY: USA
 ZIP: 77210
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: 395-395-395
 FILING DATE: 1996-06-17
 CLASSIFICATION: 4.45
 NAME: Parker, David L.
 REGISTRATION NUMBER: 42,165
 TELEPHONE: (512) 474-7577
 TELEFAX: (512) 474-7577
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 1420 base pairs
 TYPE: nucleic acid
 ORGANISM: Human
 MOLBULE TYPE: DNA (genomic)
 US 09 004 395 395

US 09 004 395 395
 Patent No. 6121419
 GENERAL INFORMATION

APPLICANT: Board of Regents
 ADDRESS: The University of Texas System
 TITLE OF INVENTION: COMBINING AND METHOD FOR
 TITLE OF INVENTION: COMBINING AND METHOD FOR
 NUMBER OF INVENTION: 8
 NUMBER OF INVENTION: 8
 CORRESPONDENCE ADDRESS:
 ADDRESS: Arnold, White & Burke
 STREET: P. O. Box 4433
 CITY: Houston
 STATE: Texas
 COUNTRY: USA
 ZIP: 77210
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: 395-395-395
 FILING DATE: 1996-06-17
 CLASSIFICATION: 4.45
 NAME: Parker, David L.
 REGISTRATION NUMBER: 42,165
 TELEPHONE: (512) 474-7577
 TELEFAX: (512) 474-7577
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 1420 base pairs
 TYPE: nucleic acid
 ORGANISM: Human
 MOLBULE TYPE: DNA (genomic)
 US 09 004 395 395

Search completed: March 23, 2002, 11:49:49
C:\Program Files\GFI\GFI Mail


```

: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO: 6057
: LENGTH: 485
: TYPE: tNA
: ORGANISM: Homo sapiens
US 09 867 701 6057

```

```

Query Match      78.1% Score 16.4 16 10 Length 485
Best Local Similarity 94.4% Prod. No. 2440002
Matches 17 Conservative 0 Mismatches 1 Indels 0 Gaps 0

```

```

QY 1 ATGAAAAGAAAATATAA 18
      1 1 1 1 1 1 1 1 1 1
DB 236 ATGAAAAGAAAATATAA 237

```

```

RESULT 11
US 09 604 387A 657
: Sequence 657 Application US/090604287A
: Patient No. US2002006872A1
: GENERAL INFORMATION:

```

```

: APPLICANT: Aliphet, Paul A.
: APPLICANT: Bannion, Jane
: TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
: TITLE OF INVENTION: AND DIAGNOSIS OF OVARIAN CANCER
: FILE REFERENCE: 210121.476
: CURRENT FILING DATE: 2001 02 05
: NUMBER OF SEQ ID NOS: 1740
: SOFTWARE: FastSeq for Window Version 4.0
: SEQ ID NO: 651
: LENGTH: 525
: TYPE: tNA
: ORGANISM: Homo sapiens
: FEATURE:
: NAME/KEY: misc_feature
: LOCATION: (1)..(525)
: OTHER INFORMATION: n A.1.0.0.0
US 09 777 564 851

```

```

Query Match      78.1% Score 16.4 16 10 Length 525
Best Local Similarity 94.4% Prod. No. 2440002
Matches 17 Conservative 0 Mismatches 1 Indels 0 Gaps 0

```

```

QY 1 ATGAAAAGAAAATATAA 18
      1 1 1 1 1 1 1 1 1 1
DB 236 ATGAAAAGAAAATATAA 237

```

```

RESULT 10
US 09 820 089A 170
: Sequence 185 Application US/10040935
: Patient No. US2002015631A1
: GENERAL INFORMATION:

```

```

: APPLICANT: Jilani, Yafiq
: APPLICANT: Jilani, Yafiq, et al.
: APPLICANT: Sengul, Mustafa
: APPLICANT: Wada, Atsuo
: APPLICANT: Stolk, John A.
: TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
: TITLE OF INVENTION: AND DIAGNOSIS OF OVARIAN CANCER
: FILE REFERENCE: 210121.5204
: CURRENT FILING DATE: 2001 02 05
: NUMBER OF SEQ ID NOS: 2239
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO: 185
: LENGTH: 557
: TYPE: tNA
: ORGANISM: Homo sapiens
: FEATURE:
: NAME/KEY: misc_feature
: LOCATION: 521

```

```

Query Match      78.1% Score 16.4 16 10 Length 557
Best Local Similarity 94.4% Prod. No. 2440002
Matches 17 Conservative 0 Mismatches 1 Indels 0 Gaps 0

```

```

QY 1 ATGAAAAGAAAATATAA 18
      1 1 1 1 1 1 1 1 1 1
DB 236 ATGAAAAGAAAATATAA 237

```

```

: OTHER INFORMATION: n A.1.0.0.0
US 09 046 965 185

```

```

Query Match      78.1% Score 16.4 16 10 Length 965
Best Local Similarity 94.4% Prod. No. 2440002
Matches 17 Conservative 0 Mismatches 1 Indels 0 Gaps 0

```

```

QY 1 ATGAAAAGAAAATATAA 18
      1 1 1 1 1 1 1 1 1 1
DB 236 ATGAAAAGAAAATATAA 237

```

```

RESULT 11
US 09 604 387A 657
: Sequence 657 Application US/090604287A
: Patient No. US2002006872A1
: GENERAL INFORMATION:

```

```

: APPLICANT: Jilani, Yafiq
: APPLICANT: Mitchell, Jonathan L.
: APPLICANT: Xu, Huiqun
: APPLICANT: Harker, Susan L.
: TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
: TITLE OF INVENTION: DIAGNOSIS OF OVARIAN CANCER
: FILE REFERENCE: 210121.47007
: CURRENT FILING DATE: 2001 02 05
: NUMBER OF SEQ ID NOS: 489
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO: 63
: LENGTH: 683
: TYPE: tNA
: ORGANISM: Homo sapiens
US 09 604 387A 63

```

```

Query Match      78.1% Score 16.4 16 10 Length 683
Best Local Similarity 94.4% Prod. No. 2440002
Matches 17 Conservative 0 Mismatches 1 Indels 0 Gaps 0

```

```

QY 1 ATGAAAAGAAAATATAA 18
      1 1 1 1 1 1 1 1 1 1
DB 236 ATGAAAAGAAAATATAA 237

```

```

RESULT 12
US 09 820 089A 170
: Sequence 3 Application US/0908086A
: Patient No. US200207250A1
: GENERAL INFORMATION:

```

```

: APPLICANT: Xu, Huiqun
: APPLICANT: Stolk, John A.
: TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
: TITLE OF INVENTION: AND DIAGNOSIS OF OVARIAN CANCER
: FILE REFERENCE: 210121.509
: CURRENT FILING DATE: 2001 02 27
: NUMBER OF SEQ ID NOS: 35
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO: 3
: LENGTH: 181
: TYPE: tNA
: ORGANISM: Homo sapiens
US 09 820 089A 3

```

```

Query Match      78.1% Score 16.4 16 10 Length 181
Best Local Similarity 94.4% Prod. No. 2440002
Matches 17 Conservative 0 Mismatches 1 Indels 0 Gaps 0

```

```

QY 1 ATGAAAAGAAAATATAA 18
      1 1 1 1 1 1 1 1 1 1
DB 236 ATGAAAAGAAAATATAA 237

```


100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

[illegible]

[illegible]

100

1. $\frac{1}{2}$
 2. $\frac{1}{3}$
 3. $\frac{1}{4}$
 4. $\frac{1}{5}$
 5. $\frac{1}{6}$
 6. $\frac{1}{7}$
 7. $\frac{1}{8}$
 8. $\frac{1}{9}$
 9. $\frac{1}{10}$
 10. $\frac{1}{11}$
 11. $\frac{1}{12}$
 12. $\frac{1}{13}$
 13. $\frac{1}{14}$
 14. $\frac{1}{15}$
 15. $\frac{1}{16}$
 16. $\frac{1}{17}$
 17. $\frac{1}{18}$
 18. $\frac{1}{19}$
 19. $\frac{1}{20}$
 20. $\frac{1}{21}$
 21. $\frac{1}{22}$
 22. $\frac{1}{23}$
 23. $\frac{1}{24}$
 24. $\frac{1}{25}$
 25. $\frac{1}{26}$
 26. $\frac{1}{27}$
 27. $\frac{1}{28}$
 28. $\frac{1}{29}$
 29. $\frac{1}{30}$
 30. $\frac{1}{31}$
 31. $\frac{1}{32}$
 32. $\frac{1}{33}$
 33. $\frac{1}{34}$
 34. $\frac{1}{35}$
 35. $\frac{1}{36}$
 36. $\frac{1}{37}$
 37. $\frac{1}{38}$
 38. $\frac{1}{39}$
 39. $\frac{1}{40}$
 40. $\frac{1}{41}$
 41. $\frac{1}{42}$
 42. $\frac{1}{43}$
 43. $\frac{1}{44}$
 44. $\frac{1}{45}$
 45. $\frac{1}{46}$
 46. $\frac{1}{47}$
 47. $\frac{1}{48}$
 48. $\frac{1}{49}$
 49. $\frac{1}{50}$
 50. $\frac{1}{51}$
 51. $\frac{1}{52}$
 52. $\frac{1}{53}$
 53. $\frac{1}{54}$
 54. $\frac{1}{55}$
 55. $\frac{1}{56}$
 56. $\frac{1}{57}$
 57. $\frac{1}{58}$
 58. $\frac{1}{59}$
 59. $\frac{1}{60}$
 60. $\frac{1}{61}$
 61. $\frac{1}{62}$
 62. $\frac{1}{63}$
 63. $\frac{1}{64}$
 64. $\frac{1}{65}$
 65. $\frac{1}{66}$
 66. $\frac{1}{67}$
 67. $\frac{1}{68}$
 68. $\frac{1}{69}$
 69. $\frac{1}{70}$
 70. $\frac{1}{71}$
 71. $\frac{1}{72}$
 72. $\frac{1}{73}$
 73. $\frac{1}{74}$
 74. $\frac{1}{75}$
 75. $\frac{1}{76}$
 76. $\frac{1}{77}$
 77. $\frac{1}{78}$
 78. $\frac{1}{79}$
 79. $\frac{1}{80}$
 80. $\frac{1}{81}$
 81. $\frac{1}{82}$
 82. $\frac{1}{83}$
 83. $\frac{1}{84}$
 84. $\frac{1}{85}$
 85. $\frac{1}{86}$
 86. $\frac{1}{87}$
 87. $\frac{1}{88}$
 88. $\frac{1}{89}$
 89. $\frac{1}{90}$
 90. $\frac{1}{91}$
 91. $\frac{1}{92}$
 92. $\frac{1}{93}$
 93. $\frac{1}{94}$
 94. $\frac{1}{95}$
 95. $\frac{1}{96}$
 96. $\frac{1}{97}$
 97. $\frac{1}{98}$
 98. $\frac{1}{99}$
 99. $\frac{1}{100}$
 100. $\frac{1}{101}$
 101. $\frac{1}{102}$
 102. $\frac{1}{103}$
 103. $\frac{1}{104}$
 104. $\frac{1}{105}$
 105. $\frac{1}{106}$
 106. $\frac{1}{107}$
 107. $\frac{1}{108}$
 108. $\frac{1}{109}$
 109. $\frac{1}{110}$
 110. $\frac{1}{111}$
 111. $\frac{1}{112}$
 112. $\frac{1}{113}$
 113. $\frac{1}{114}$
 114. $\frac{1}{115}$
 115. $\frac{1}{116}$
 116. $\frac{1}{117}$
 117. $\frac{1}{118}$
 118. $\frac{1}{119}$
 119. $\frac{1}{120}$
 120. $\frac{1}{121}$
 121. $\frac{1}{122}$
 122. $\frac{1}{123}$
 123. $\frac{1}{124}$
 124. $\frac{1}{125}$
 125. $\frac{1}{126}$
 126. $\frac{1}{127}$
 127. $\frac{1}{128}$
 128. $\frac{1}{129}$
 129. $\frac{1}{130}$
 130. $\frac{1}{131}$
 131. $\frac{1}{132}$
 132. $\frac{1}{133}$
 133. $\frac{1}{134}$
 134. $\frac{1}{135}$
 135. $\frac{1}{136}$
 136. $\frac{1}{137}$
 137. $\frac{1}{138}$
 138. $\frac{1}{139}$
 139. $\frac{1}{140}$
 140. $\frac{1}{141}$
 141. $\frac{1}{142}$
 142. $\frac{1}{143}$
 143. $\frac{1}{144}$
 144. $\frac{1}{145}$
 145. $\frac{1}{146}$
 146. $\frac{1}{147}$
 147. $\frac{1}{148}$
 148. $\frac{1}{149}$
 149. $\frac{1}{150}$
 150. $\frac{1}{151}$
 151. $\frac{1}{152}$
 152. $\frac{1}{153}$
 153. $\frac{1}{154}$
 154. $\frac{1}{155}$
 155. $\frac{1}{156}$
 156. $\frac{1}{157}$
 157. $\frac{1}{158}$
 158. $\frac{1}{159}$
 159. $\frac{1}{160}$
 160. $\frac{1}{161}$
 161. $\frac{1}{162}$
 162. $\frac{1}{163}$
 163. $\frac{1}{164}$
 164. $\frac{1}{165}$
 165. $\frac{1}{166}$
 166. $\frac{1}{167}$
 167. $\frac{1}{168}$
 168. $\frac{1}{169}$
 169. $\frac{1}{170}$
 170. $\frac{1}{171}$
 171. $\frac{1}{172}$
 172. $\frac{1}{173}$
 173. $\frac{1}{174}$
 174. $\frac{1}{175}$
 175. $\frac{1}{176}$
 176. $\frac{1}{177}$
 177. $\frac{1}{178}$
 178. $\frac{1}{179}$
 179. $\frac{1}{180}$
 180. $\frac{1}{181}$
 181. $\frac{1}{182}$
 182. $\frac{1}{183}$
 183. $\frac{1}{184}$
 184. $\frac{1}{185}$
 185. $\frac{1}{186}$
 186. $\frac{1}{187}$
 187. $\frac{1}{188}$
 188. $\frac{1}{189}$
 189. $\frac{1}{190}$
 190. $\frac{1}{191}$
 191. $\frac{1}{192}$
 192. $\frac{1}{193}$
 193. $\frac{1}{194}$
 194. $\frac{1}{195}$
 195. $\frac{1}{196}$
 196. $\frac{1}{197}</$

Wolff, J. J. and A. J. A.

[illegible]

Abstract

2.4. Materials

1000

1

[illegible][illegible]

$\frac{d}{dt} \left(\frac{\partial L}{\partial \dot{x}} \right) = \frac{\partial L}{\partial x}$

[illegible]

11-2-2010

— 10 —

$$\text{sign}(S_i) = \begin{cases} 1, & \text{if } S_i \geq 0 \\ -1, & \text{if } S_i < 0 \end{cases}$$

(A113573, A113574).

[illegible][illegible]

100

—

41 MAY 1965

Figure 1 consists of two panels of Western blots. The top panel shows p38 phosphorylation in whole cell lysates from 3T3-L1 adipocytes treated with 100 nM rosiglitazone for 0, 15, 30, 60, and 120 minutes. The bottom panel shows p38 phosphorylation in whole cell lysates from 3T3-L1 adipocytes treated with 100 nM rosiglitazone for 0, 15, 30, 60, and 120 minutes, with or without 100 nM LY293784. Molecular weight markers are indicated on the left of each panel.

[illegible][illegible]

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.



Topology: Linear
Molecule type: protein
US 09 159 469 74

Query Match
Best local similarity: 42.8% (ID: No. 614)
Matches: 60; Conservative: 61; Mismatches: 101; Gaps: 26

97 74 DMVY LGGKNSVLLRMMGLAVSR - YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
100 LMMVRLRSLR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
99 112 Y FVAVAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
101 SYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
98 167 KKKVSVL VETL LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
104 VVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
95 212 SDVYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
103 SYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
97 266 KKKVSVL VETL LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
100 SYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111

RESULT 2

US 09 159 469 74
Sequence 74, Application US/09/159469
Patent No. US 2002/006846A1

GENERAL INFORMATION

APPLICANT: Reed, Steven G.
APPLICANT: Lodos, Michael J.
APPLICANT: Lodos, Michael J.
APPLICANT: Lodos, Michael J.
TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE TREATMENT OF BIRCHALLA INFECTION
FILE REFERENCE: 2002/14097
CURRENT APPLICANT: BERGER, 09/07/98, 012
CURRENT FILING DATE: 2001/03/02
NUMBER OF SEQ ID NOS: 106
SOFTWARE: FASTSEQ For Windows Version 1.0
SEQ ID NO: 74
LENGTH: 546
TYPE: 101
ORGANISM: Ehrlichia sp.

US 09 159 469 74

Query Match
Best local similarity: 42.8% (ID: No. 614)
Matches: 60; Conservative: 61; Mismatches: 101; Gaps: 26

97 74 DMVY LGGKNSVLLRMMGLAVSR - YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
100 LMMVRLRSLR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
99 112 Y FVAVAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
101 SYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
98 167 KKKVSVL VETL LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
104 VVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
95 212 SDVYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
103 SYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
97 266 KKKVSVL VETL LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111

US 09 159 469 74
Sequence 74, Application US/09/159469
Patent No. US 2002/006846A1

GENERAL INFORMATION

APPLICANT: Reed, Steven G.
APPLICANT: Lodos, Michael J.
APPLICANT: Lodos, Michael J.
APPLICANT: Lodos, Michael J.
TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE TREATMENT OF BIRCHALLA INFECTION
FILE REFERENCE: 2002/14097
CURRENT APPLICANT: BERGER, 09/07/98, 012
CURRENT FILING DATE: 2001/03/02
NUMBER OF SEQ ID NOS: 106
SOFTWARE: FASTSEQ For Windows Version 1.0
SEQ ID NO: 74
LENGTH: 546
TYPE: 101
ORGANISM: Ehrlichia sp.

US 09 159 469 74

Query Match
Best local similarity: 42.8% (ID: No. 614)
Matches: 60; Conservative: 61; Mismatches: 101; Gaps: 26

97 74 DMVY LGGKNSVLLRMMGLAVSR - YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
100 LMMVRLRSLR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
99 112 Y FVAVAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
101 SYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
98 167 KKKVSVL VETL LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
104 VVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
95 212 SDVYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
103 SYVRLRMMGLAVSR LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111
97 266 KKKVSVL VETL LGGKNSVLLRMMGLAVSR YVAVAVSR 111
111 111 111 111 111 111 111 111 111 111


```

1  APPLICANT: Yehon, Xie
2  APPLICANT: 2000-11-27
3  TITLE OF INVENTION: Nucleic Acid Sequencing Method for Identifying and
4  TITLE OF INVENTION: Nucleic Acid Sequencing Method for Identifying and
5  FILE REFERENCE: US 6,242,442
6  CURRENT FILING DATE: 2001-12-22
7  PRIOR FILING DATE: 2001-12-22
8  PRIOR FILING DATE: 2001-12-22
9  PRIOR FILING DATE: 2001-12-22
10  PRIOR FILING DATE: 2001-12-22
11  PRIOR FILING DATE: 2001-12-22
12  PRIOR FILING DATE: 2001-12-22
13  PRIOR FILING DATE: 2001-12-22
14  PRIOR FILING DATE: 2001-12-22
15  PRIOR FILING DATE: 2001-12-22
16  PRIOR FILING DATE: 2001-12-22
17  PRIOR FILING DATE: 2001-12-22
18  PRIOR FILING DATE: 2001-12-22
19  PRIOR FILING DATE: 2001-12-22
20  PRIOR FILING DATE: 2001-12-22
21  PRIOR FILING DATE: 2001-12-22
22  PRIOR FILING DATE: 2001-12-22
23  PRIOR FILING DATE: 2001-12-22
24  PRIOR FILING DATE: 2001-12-22
25  PRIOR FILING DATE: 2001-12-22
26  PRIOR FILING DATE: 2001-12-22
27  PRIOR FILING DATE: 2001-12-22
28  PRIOR FILING DATE: 2001-12-22
29  PRIOR FILING DATE: 2001-12-22
30  PRIOR FILING DATE: 2001-12-22
31  PRIOR FILING DATE: 2001-12-22
32  PRIOR FILING DATE: 2001-12-22
33  PRIOR FILING DATE: 2001-12-22
34  PRIOR FILING DATE: 2001-12-22
35  PRIOR FILING DATE: 2001-12-22
36  PRIOR FILING DATE: 2001-12-22
37  PRIOR FILING DATE: 2001-12-22
38  PRIOR FILING DATE: 2001-12-22
39  PRIOR FILING DATE: 2001-12-22
40  PRIOR FILING DATE: 2001-12-22
41  PRIOR FILING DATE: 2001-12-22
42  PRIOR FILING DATE: 2001-12-22
43  PRIOR FILING DATE: 2001-12-22
44  PRIOR FILING DATE: 2001-12-22
45  PRIOR FILING DATE: 2001-12-22
46  PRIOR FILING DATE: 2001-12-22
47  PRIOR FILING DATE: 2001-12-22
48  PRIOR FILING DATE: 2001-12-22
49  PRIOR FILING DATE: 2001-12-22
50  PRIOR FILING DATE: 2001-12-22
51  PRIOR FILING DATE: 2001-12-22
52  PRIOR FILING DATE: 2001-12-22
53  PRIOR FILING DATE: 2001-12-22
54  PRIOR FILING DATE: 2001-12-22
55  PRIOR FILING DATE: 2001-12-22
56  PRIOR FILING DATE: 2001-12-22
57  PRIOR FILING DATE: 2001-12-22
58  PRIOR FILING DATE: 2001-12-22
59  PRIOR FILING DATE: 2001-12-22
60  PRIOR FILING DATE: 2001-12-22
61  PRIOR FILING DATE: 2001-12-22
62  PRIOR FILING DATE: 2001-12-22
63  PRIOR FILING DATE: 2001-12-22
64  PRIOR FILING DATE: 2001-12-22
65  PRIOR FILING DATE: 2001-12-22
66  PRIOR FILING DATE: 2001-12-22
67  PRIOR FILING DATE: 2001-12-22
68  PRIOR FILING DATE: 2001-12-22
69  PRIOR FILING DATE: 2001-12-22
70  PRIOR FILING DATE: 2001-12-22
71  PRIOR FILING DATE: 2001-12-22
72  PRIOR FILING DATE: 2001-12-22
73  PRIOR FILING DATE: 2001-12-22
74  PRIOR FILING DATE: 2001-12-22
75  PRIOR FILING DATE: 2001-12-22
76  PRIOR FILING DATE: 2001-12-22
77  PRIOR FILING DATE: 2001-12-22
78  PRIOR FILING DATE: 2001-12-22
79  PRIOR FILING DATE: 2001-12-22
80  PRIOR FILING DATE: 2001-12-22
81  PRIOR FILING DATE: 2001-12-22
82  PRIOR FILING DATE: 2001-12-22
83  PRIOR FILING DATE: 2001-12-22
84  PRIOR FILING DATE: 2001-12-22
85  PRIOR FILING DATE: 2001-12-22
86  PRIOR FILING DATE: 2001-12-22
87  PRIOR FILING DATE: 2001-12-22
88  PRIOR FILING DATE: 2001-12-22
89  PRIOR FILING DATE: 2001-12-22
90  PRIOR FILING DATE: 2001-12-22
91  PRIOR FILING DATE: 2001-12-22
92  PRIOR FILING DATE: 2001-12-22
93  PRIOR FILING DATE: 2001-12-22
94  PRIOR FILING DATE: 2001-12-22
95  PRIOR FILING DATE: 2001-12-22
96  PRIOR FILING DATE: 2001-12-22
97  PRIOR FILING DATE: 2001-12-22
98  PRIOR FILING DATE: 2001-12-22
99  PRIOR FILING DATE: 2001-12-22
100 PRIOR FILING DATE: 2001-12-22

```


100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

140 GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH 237
 141 GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH 168
 142 GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH 247
 143 GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH 224
 144 GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH 304
 145 GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH 274
 146 GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH 301

GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH
 GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH GOSCHENOVICH

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

10:58:37 2002

106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Art, Charles E., Bowman, C., Garland, S., Fujili, C., Gorton, M., Ho, R.,
Robert, K., and Baker, S. and others. *Genetic*

Direct Sequencing

Submitted: 11/05/02; the last update for genomic resources: 12/14/02

Medical Center Dr., Rockville, MD 20850, USA

Location: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

Accession: 100110

RE submissi.":
 AC BLAST: 23/03/1997).
 CC 1. CONTACT: POTENTIAL PHOSPHATE (POTENTIAL).
 CC 2. CATALYTIC: IN THE 3' TERMINAL 1 AMIN TRANSFERASE.
 CC
 CC this SWISS-Prot entry is copyright. It is provided for out- of- house use
 CC between the Swiss Institute of Bioinformatics and the EMBL and SIB
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in the way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.ebi.ac.uk/edm/>)
 CC or send an email to license@ebi.ac.uk.
 CC
 DR EMBL: X70463; CAA04211; .
 DR EMBL: 568454; BAA06911; .
 DR EMBL: 299105; CAA12164.1; .
 DR EMBL: 299106; CAA12164.1; .
 DR EMBL: 299107; CAA12164.1; .
 DR EMBL: 299108; CAA12164.1; .
 DR EMBL: 299109; CAA12164.1; .
 DR EMBL: 299110; CAA12164.1; .
 DR EMBL: 299111; CAA12164.1; .
 DR EMBL: 299112; CAA12164.1; .
 DR EMBL: 299113; CAA12164.1; .
 DR EMBL: 299114; CAA12164.1; .
 DR EMBL: 299115; CAA12164.1; .
 DR EMBL: 299116; CAA12164.1; .
 DR EMBL: 299117; CAA12164.1; .
 DR EMBL: 299118; CAA12164.1; .
 DR EMBL: 299119; CAA12164.1; .
 DR EMBL: 299120; CAA12164.1; .
 DR EMBL: 299121; CAA12164.1; .
 DR EMBL: 299122; CAA12164.1; .
 DR EMBL: 299123; CAA12164.1; .
 DR EMBL: 299124; CAA12164.1; .
 DR EMBL: 299125; CAA12164.1; .
 DR EMBL: 299126; CAA12164.1; .
 DR EMBL: 299127; CAA12164.1; .
 DR EMBL: 299128; CAA12164.1; .
 DR EMBL: 299129; CAA12164.1; .
 DR EMBL: 299130; CAA12164.1; .
 DR EMBL: 299131; CAA12164.1; .
 DR EMBL: 299132; CAA12164.1; .
 DR EMBL: 299133; CAA12164.1; .
 DR EMBL: 299134; CAA12164.1; .
 DR EMBL: 299135; CAA12164.1; .
 DR EMBL: 299136; CAA12164.1; .
 DR EMBL: 299137; CAA12164.1; .
 DR EMBL: 299138; CAA12164.1; .
 DR EMBL: 299139; CAA12164.1; .
 DR EMBL: 299140; CAA12164.1; .
 DR EMBL: 299141; CAA12164.1; .
 DR EMBL: 299142; CAA12164.1; .
 DR EMBL: 299143; CAA12164.1; .
 DR EMBL: 299144; CAA12164.1; .
 DR EMBL: 299145; CAA12164.1; .
 DR EMBL: 299146; CAA12164.1; .
 DR EMBL: 299147; CAA12164.1; .
 DR EMBL: 299148; CAA12164.1; .
 DR EMBL: 299149; CAA12164.1; .
 DR EMBL: 299150; CAA12164.1; .
 DR EMBL: 299151; CAA12164.1; .
 DR EMBL: 299152; CAA12164.1; .
 DR EMBL: 299153; CAA12164.1; .
 DR EMBL: 299154; CAA12164.1; .
 DR EMBL: 299155; CAA12164.1; .
 DR EMBL: 299156; CAA12164.1; .
 DR EMBL: 299157; CAA12164.1; .
 DR EMBL: 299158; CAA12164.1; .
 DR EMBL: 299159; CAA12164.1; .
 DR EMBL: 299160; CAA12164.1; .
 DR EMBL: 299161; CAA12164.1; .
 DR EMBL: 299162; CAA12164.1; .
 DR EMBL: 299163; CAA12164.1; .
 DR EMBL: 299164; CAA12164.1; .
 DR EMBL: 299165; CAA12164.1; .
 DR EMBL: 299166; CAA12164.1; .
 DR EMBL: 299167; CAA12164.1; .
 DR EMBL: 299168; CAA12164.1; .
 DR EMBL: 299169; CAA12164.1; .
 DR EMBL: 299170; CAA12164.1; .
 DR EMBL: 299171; CAA12164.1; .
 DR EMBL: 299172; CAA12164.1; .
 DR EMBL: 299173; CAA12164.1; .
 DR EMBL: 299174; CAA12164.1; .
 DR EMBL: 299175; CAA12164.1; .
 DR EMBL: 299176; CAA12164.1; .
 DR EMBL: 299177; CAA12164.1; .
 DR EMBL: 299178; CAA12164.1; .
 DR EMBL: 299179; CAA12164.1; .
 DR EMBL: 299180; CAA12164.1; .
 DR EMBL: 299181; CAA12164.1; .
 DR EMBL: 299182; CAA12164.1; .
 DR EMBL: 299183; CAA12164.1; .
 DR EMBL: 299184; CAA12164.1; .
 DR EMBL: 299185; CAA12164.1; .
 DR EMBL: 299186; CAA12164.1; .
 DR EMBL: 299187; CAA12164.1; .
 DR EMBL: 299188; CAA12164.1; .
 DR EMBL: 299189; CAA12164.1; .
 DR EMBL: 299190; CAA12164.1; .
 DR EMBL: 299191; CAA12164.1; .
 DR EMBL: 299192; CAA12164.1; .
 DR EMBL: 299193; CAA12164.1; .
 DR EMBL: 299194; CAA12164.1; .
 DR EMBL: 299195; CAA12164.1; .
 DR EMBL: 299196; CAA12164.1; .
 DR EMBL: 299197; CAA12164.1; .
 DR EMBL: 299198; CAA12164.1; .
 DR EMBL: 299199; CAA12164.1; .
 DR EMBL: 299200; CAA12164.1; .
 DR EMBL: 299201; CAA12164.1; .
 DR EMBL: 299202; CAA12164.1; .
 DR EMBL: 299203; CAA12164.1; .
 DR EMBL: 299204; CAA12164.1; .
 DR EMBL: 299205; CAA12164.1; .
 DR EMBL: 299206; CAA12164.1; .
 DR EMBL: 299207; CAA12164.1; .
 DR EMBL: 299208; CAA12164.1; .
 DR EMBL: 299209; CAA12164.1; .
 DR EMBL: 299210; CAA12164.1; .
 DR EMBL: 299211; CAA12164.1; .
 DR EMBL: 299212; CAA12164.1; .
 DR EMBL: 299213; CAA12164.1; .
 DR EMBL: 299214; CAA12164.1; .
 DR EMBL: 299215; CAA12164.1; .
 DR EMBL: 299216; CAA12164.1; .
 DR EMBL: 299217; CAA12164.1; .
 DR EMBL: 299218; CAA12164.1; .
 DR EMBL: 299219; CAA12164.1; .
 DR EMBL: 299220; CAA12164.1; .
 DR EMBL: 299221; CAA12164.1; .
 DR EMBL: 299222; CAA12164.1; .
 DR EMBL: 299223; CAA12164.1; .
 DR EMBL: 299224; CAA12164.1; .
 DR EMBL: 299225; CAA12164.1; .
 DR EMBL: 299226; CAA12164.1; .
 DR EMBL: 299227; CAA12164.1; .
 DR EMBL: 299228; CAA12164.1; .
 DR EMBL: 299229; CAA12164.1; .
 DR EMBL: 299230; CAA12164.1; .
 DR EMBL: 299231; CAA12164.1; .
 DR EMBL: 299232; CAA12164.1; .
 DR EMBL: 299233; CAA12164.1; .
 DR EMBL: 299234; CAA12164.1; .
 DR EMBL: 299235; CAA12164.1;




```

LR WP: 2002 100000/17.
XX Nucleic acid comprised fragment of chemically modified gene, used for
PI for diagnostics and treatment of diseases associated with abnormal
XX cytosine methylation
XX C. crum 1: SEQ ID NO 1251: 544 - Sequence Listing: German.
XX The present invention provides a number of human immune system associated
XX genes which are modified by the methylation of cytosines. The sequences
XX can be used in the diagnosis and treatment of immune system disorders,
XX including eye diseases such as retinopathy, neovascular glaucoma and
XX macular degeneration, arteriosclerosis, anemia, cancer, acute myeloid
XX leukemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
XX rheumatoid arthritis, psoriasis and inflammatory/alcerative bowel
XX diseases. The present sequence is a gene of the invention.
XX Sequence 1251: 307 2116 A: 40 27 109 G: 4738 1: 0 other:
XX
XX 2002 Match 4 600 Score 76.63 DB 24: Length 1255;
XX Best Local Similarity 48.08 Prod. No. 0.00048;
XX Matches 274: Conservation 0: Mismatches 239: Indels 4: Gaps 2:
XX
XX 3 GATAGATCTTTTTCAGAAAGAGTTTCTTATCTTATCTAGCAAGGATTGTCCTAAI 62
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4 308 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 122
XX 4438 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4507
XX 4438 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 182
XX 4508 AATCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4567
XX 4508 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 239
XX 4568 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4627
XX 4568 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 299
XX 4628 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4687
XX 4628 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 359
XX 4688 AATCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4746
XX 4688 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 419
XX 4688 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4806
XX 4747 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4806
XX 4747 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 479
XX 4747 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4869
XX 4747 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 539
XX 4869 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4929
XX 4869 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 566
XX 4869 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT
XX 4953

```

Search completed: November 4, 2002, 20:49:49
 File size: 464,736 bytes


```

14 406 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 111111 1
07 412 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 461
14 412 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 404
07 412 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 511
14 412 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 253
RESULT 5
US 09-004-395-104
SEQUENCE 106, Application 404, 09-004-395-104
GENERAL INFORMATION:
APPLICANT: Philipsson, Peter
APPLICANT: Frederick, Sabine
APPLICANT: Strohm, Sabine
APPLICANT: Mohr, Christine
APPLICANT: Wendland, Jürgen
APPLICANT: Kuechler, Philipp
APPLICANT: Reischardt, Christine
TITLE OF INVENTION: GER-MIT-LGA SEQUENCES OF ASHWA G-SSPFI
NUMBER OF SEQUENCES: 1152
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 629264artis Corporation
STREET: 4054 Cornwallis Road
CITY: Research Triangle Park
STATE: No. 629264th Carolina
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPILED: IBM PC compatible
OPERATING SYSTEM: PC DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICANT NUMBER: 09-004-395-104
FILING DATE: 24 Dec 1997
PRIOR APPLICATION DATA:
CLASSIFICATION: 46
APPLICATION NUMBER: CH 0017/97
FILING DATE: 31 Dec 1996
ATTORNEY/AGENT INFORMATION:
NAME: Mohr, J. Timothy
REGISTRATION NUMBER: 46,241
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8587
INVENTOR INFORMATION:
LENGTH: 616 base pairs
TYPE: nucleic acid
SEQUENCE: single
Topology: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
CHARACTER: FA 110748
US 09-004-395-106
Query Match: 674; Score 61.8; E-Val 4; Length 616;
Best Local Similarity: 47.8%; Prod. Ratio 0.27
Matches: 211; Characterive: 6; Mismatches: 227; Indels: 4; Gaps: 1.
07 76 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 134
14 10 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 69

```

```

07 136 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 130
14 70 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 129
07 192 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 253
14 120 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 139
07 252 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 312
14 190 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 139
07 312 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 473
14 270 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 431
07 372 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 431
14 310 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 399
07 432 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 494
14 370 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 429
07 492 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 494
14 430 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 429
RESULT 6
US 09-004-395-1187
SEQUENCE 117, Application 09-004-395-1187
Patent No. 629264
GENERAL INFORMATION:
APPLICANT: Philipsson, Peter
APPLICANT: Reischardt, Christine
APPLICANT: Strohm, Sabine
APPLICANT: Mohr, Christine
APPLICANT: Wendland, Jürgen
APPLICANT: Kuechler, Philipp
APPLICANT: Reischardt, Christine
TITLE OF INVENTION: GER-MIT-LGA SEQUENCES OF ASHWA G-SSPFI
NUMBER OF SEQUENCES: 1152
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 629264artis Corporation
STREET: 4054 Cornwallis Road
CITY: Research Triangle Park
STATE: No. 629264th Carolina
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPILED: IBM PC compatible
OPERATING SYSTEM: PC DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICANT NUMBER: 09-004-395-1187
FILING DATE: 24 Dec 1997
CLASSIFICATION: 46
PRIOR APPLICATION DATA:
APPLICATION NUMBER: CH 017/97
FILING DATE: 31 Dec 1996
ATTORNEY/AGENT INFORMATION:
NAME: Mohr, J. Timothy
REGISTRATION NUMBER: 46,241
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8587
INVENTOR INFORMATION:
LENGTH: 616 base pairs

```


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. The text outlines various methods for organizing and storing records, including digital databases and physical filing systems. It also mentions the need for regular audits and reviews to ensure the integrity and accuracy of the data.

2. The second part of the document focuses on the role of communication in achieving organizational goals. It highlights the importance of clear and concise communication, both internally and externally. The text provides guidelines for effective communication, such as using appropriate language, listening actively, and providing feedback. It also discusses the benefits of open communication, including improved collaboration and decision-making.

3. The third part of the document addresses the issue of risk management. It defines risk as the potential for loss or damage and explains how to identify, assess, and mitigate risks. The text provides a framework for risk management, including the identification of risks, the assessment of their likelihood and impact, and the implementation of control measures. It also discusses the importance of monitoring and reviewing risks over time.

4. The fourth part of the document discusses the importance of training and development. It emphasizes that ongoing training and development are essential for maintaining a skilled and motivated workforce. The text outlines various training methods, including classroom instruction, on-the-job training, and self-directed learning. It also discusses the importance of setting learning objectives and evaluating the effectiveness of training programs.

5. The fifth part of the document discusses the importance of innovation and creativity. It emphasizes that innovation and creativity are essential for staying competitive in a rapidly changing market. The text provides guidelines for fostering innovation and creativity, such as encouraging open-mindedness, providing resources, and creating a supportive environment. It also discusses the importance of protecting intellectual property and promoting collaboration.

6. The sixth part of the document discusses the importance of sustainability. It defines sustainability as the ability to meet the needs of the present without compromising the ability of future generations to meet their own needs. The text outlines various strategies for achieving sustainability, including reducing environmental impact, promoting social responsibility, and ensuring financial viability. It also discusses the importance of measuring and reporting on sustainability performance.

7. The seventh part of the document discusses the importance of ethics and integrity. It emphasizes that ethics and integrity are essential for building trust and maintaining a positive reputation. The text provides guidelines for ethical behavior, such as being honest, fair, and respectful. It also discusses the importance of establishing a code of ethics and providing training on ethical issues.

8. The eighth part of the document discusses the importance of leadership. It emphasizes that effective leadership is essential for achieving organizational goals. The text outlines various leadership styles, including autocratic, democratic, and transformational. It also discusses the importance of setting a vision, inspiring others, and providing support.

9. The ninth part of the document discusses the importance of teamwork. It emphasizes that teamwork is essential for achieving complex tasks and goals. The text provides guidelines for effective teamwork, such as setting clear roles and responsibilities, communicating effectively, and providing support. It also discusses the importance of building trust and fostering a positive team culture.

10. The tenth part of the document discusses the importance of change management. It emphasizes that change is a constant in business and that effective change management is essential for navigating change successfully. The text outlines various change management models, including the ADKAR model and the Kotter model. It also discusses the importance of communicating the need for change and providing support during the transition.

